# AL-433

Source: https://onco.cc/drugs/al-433/  
OnCo record `al-433` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AL-433 is an experimental small molecule from Alaw Therapeutics, in preclinical development for solid tumours.

## Summary

AL-433 is a small molecule from Alaw Therapeutics. A selective, brain-penetrant CDK4 inhibitor engineered for selectivity over CDK6, intended to reduce CDK6-related blood toxicity; it targets tumours driven by the CDK4-cyclin D1-Rb-E2F axis. Its furthest stage is preclinical development, for solid tumours (indication not specified). No clinical trial naming it is registered on ClinicalTrials.gov. Nominated as a development candidate on 29 May 2026; first-in-human studies planned for the fourth quarter of 2026. No registered trial found. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: AL-433
- Modality: Small molecule
- Mechanism: A selective, brain-penetrant CDK4 inhibitor engineered for selectivity over CDK6, intended to reduce CDK6-related blood toxicity; it targets tumours driven by the CDK4-cyclin D1-Rb-E2F axis.

## Sources

- Alaw Therapeutics: alawtx.com: https://www.alawtx.com/news1/alaw-therapeutics-announces-two-major-pipeline-milestones-advancing-brain-penetrant-cdk-oncology-programs
- Alaw Therapeutics: alawtx.com: https://www.alawtx.com/news1/alaw-therapeutics-announces-two-major-pipeline-milestones-advancing-brain-penetrant-cdk-oncology-programs

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Alaw Therapeutics](https://onco.cc/companies/alaw-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/al-433.json